2 completed. 2 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 2 | Completed 2 |
Follow Jonathan A. Bernstein, MD: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Utility of Functionally Relevant Signature Genes in Assessing the Clinical Outcomes of Dupilumab Treatment Dupilumab Prefilled Syringe - Atopic Dermatitis, Eczema | Phase 4 | Completed | Jonathan A. Bernstein, MD | 12 | 2020-09-01 | 2023-02-08 |
| Treatment of Chronic Urticarial Unresponsive to H1-antihistamines With an Anti-IL5Ralpha Monoclonal Antibody benralizumab, placebo - Chronic Idiopathic Urticaria | Phase 4 | Completed | Jonathan A. Bernstein, MD | 12 | 2017-09-12 | 2019-07-10 |
Chronic Urticaria (1) · Dermatitis, Atopic (1) · Eczema (1)
benralizumab (1) · dupilumab (1)
United States (2)